Researchers are planning a clinical trial to find out which dose of the blood thinner heparin works best for patients having an elective heart procedure called percutaneous coronary intervention (PCI). The study will compare a lower dose (70 units per kilogram of body weight) against the standard higher dose (100 units/kg) that is often used. The trial will involve patients at 11 medical centers in Ontario, Canada.
The main goal of the trial is to see which dose leads to better outcomes for patients within 30 days after their procedure. The researchers will look at a combination of serious events, including death, heart attack, or the need for another procedure on the same blood vessel. They will also track major bleeding events to understand the safety of each dose.
It is very important to understand that this is a planning paper. It only explains how the trial will be set up and what questions it aims to answer. No patients have been treated yet under this study plan, and there are no results to report on whether one dose is safer or more effective than the other. Readers should know that this is the first step in a research process, and it will likely be years before final answers are available.